SI-BONE, Inc. (NASDAQ:SIBN) Given Average Rating of “Buy” by Analysts

Shares of SI-BONE, Inc. (NASDAQ:SIBN) have been assigned a consensus rating of “Buy” from the six brokerages that are covering the company, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy rating. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $23.00.

A number of research analysts have recently issued reports on the stock. Needham & Company LLC reiterated a “buy” rating and set a $19.00 price target on shares of SI-BONE in a research note on Monday, January 13th. Truist Financial boosted their price target on shares of SI-BONE from $16.00 to $18.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th.

SI-BONE Price Performance

Shares of NASDAQ:SIBN opened at $18.10 on Thursday. SI-BONE has a one year low of $11.70 and a one year high of $21.64. The company has a debt-to-equity ratio of 0.22, a quick ratio of 7.22 and a current ratio of 8.25. The company has a 50-day simple moving average of $14.80 and a 200-day simple moving average of $14.52. The stock has a market capitalization of $759.11 million, a price-to-earnings ratio of -19.67 and a beta of 1.17.

Insiders Place Their Bets

In other SI-BONE news, CEO Laura Francis sold 10,048 shares of the company’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $12.58, for a total transaction of $126,403.84. Following the transaction, the chief executive officer now directly owns 482,875 shares in the company, valued at approximately $6,074,567.50. This represents a 2.04 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Anshul Maheshwari sold 2,439 shares of the company’s stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $12.68, for a total transaction of $30,926.52. Following the transaction, the chief financial officer now owns 194,623 shares in the company, valued at $2,467,819.64. The trade was a 1.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 27,344 shares of company stock worth $357,292. 3.90% of the stock is owned by company insiders.

Institutional Trading of SI-BONE

Large investors have recently modified their holdings of the business. Jane Street Group LLC grew its position in shares of SI-BONE by 29.0% in the third quarter. Jane Street Group LLC now owns 77,359 shares of the company’s stock valued at $1,081,000 after purchasing an additional 17,410 shares during the last quarter. Millrace Asset Group Inc. acquired a new stake in shares of SI-BONE in the third quarter valued at approximately $1,056,000. Champlain Investment Partners LLC grew its position in shares of SI-BONE by 14.7% in the third quarter. Champlain Investment Partners LLC now owns 2,800,073 shares of the company’s stock valued at $39,145,000 after purchasing an additional 358,821 shares during the last quarter. Impax Asset Management Group plc grew its position in shares of SI-BONE by 41.3% in the third quarter. Impax Asset Management Group plc now owns 758,521 shares of the company’s stock valued at $10,604,000 after purchasing an additional 221,604 shares during the last quarter. Finally, Franklin Resources Inc. grew its position in shares of SI-BONE by 9.4% in the third quarter. Franklin Resources Inc. now owns 20,220 shares of the company’s stock valued at $265,000 after purchasing an additional 1,745 shares during the last quarter. 98.11% of the stock is currently owned by institutional investors and hedge funds.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.